Thanks very much. We do appreciate you both coming back.
The issue that was raised, I think, by the candidates for this facility.... They raise some concerns about the Gates study and whether or not, really, there is a difference between a theoretical capacity around the world to be able to produce enough vaccine for a pilot project and a practical on-the-ground reality of that capacity.
I would like to hear from both of you--in particular you, Dr. Plummer--that if you had a terrific candidate for a clinical trial, without this new facility, do you believe that the commercial producers of vaccine would be prepared to stop their lines in the middle of a flu epidemic to make enough vaccine for your study or clinical trial? I think what we learned in the fall around H1N1 is that we didn't even have the capacity to make two different vaccines at the same time. We actually had to stop one and start the next, and it really did cause problems.
How would a commercial enterprise, which is accountable to its shareholders, stop a commercial run in order to make enough vaccine for you to be able to do your clinical trial?